Although the introduction of biological treatments, including tumor necrosis factor (TNF)-α antagonists (Efalizumab), anti-TNF antibody (Adalimumab) (16), IL-12/interleukin-23 (IL-23) antagonists (Ustekinumab) (17), and interleukin-17 (IL-17) antagonists (Secukinumab, Ixekizumab, and Brodalumab) (18, 19), has revolutionized the short-term treatment of moderate-to-severe plaque psoriasis, the long-term use of biological therapies may cause loss of efficacy as well as severe adverse reactions, such as infection, cancer, and hepatic dysfunction (20, 21) (Table 2). Here, IL37 is linked to infection.